comparemela.com

Latest Breaking News On - Cornerstone pharmaceuticals - Page 5 : comparemela.com

EMA grants orphan drug designation to Cornerstone Pharmaceuticals CPI-613 (devimistat)

Cornerstone Pharmaceuticals has announced that the European Medicines Agency (EMA) has granted orphan drug designation (ODD) to CPI-613 (devimistat) to treat advanced unresectable biliary tract cancer.

United kingdomVaibhav sahaiSanjeev lutherDrug administrationCornerstone pharmaceuticals

EMA Grants Orphan Drug Designation to Cornerstone Pharmaceuticals CPI-613 for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer (RFL)

EMA Grants Orphan Drug Designation to Cornerstone Pharmaceuticals CPI-613 for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer (RFL)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesVaibhav sahaiSanjeev lutherEuropean medicines agencyRafael pharmaceuticalsDrug administrationCornerstone pharmaceuticalsCornerstone pharmaceuticals inc

European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals CPI-613 (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer Seite 1

24.05.2022 - Cranbury, NJ, May 24, 2022 (GLOBE NEWSWIRE) - Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced that the European . Seite 1

United statesVaibhav sahaiSanjeev lutherDrug administrationCornerstone pharmaceuticals

Rafael Pharmaceuticals, Inc Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc

19.05.2022 - Company name change reflects mission to address significant unmet needs in rare cancer therapeutics, returning to company rootsCranbury, NJ, May 19, 2022 (GLOBE NEWSWIRE) - Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company .

Morrena villanuevaEuropean medicines agencyDrug administrationCornerstone pharmaceuticalsCornerstone pharmaceuticals inc

Study reveals how pancreatic tumors program macrophages to construct fibrotic barriers

In the presence of pancreatic tumors, certain immune cells break down structural proteins into molecules that trigger the building of dense tissue, a known barrier to therapy, a new study finds.

United statesJoseph pucciniSaulj farberAlec kimmelmanMadeleine larueSeth parkerEmily hendersonMichael cammerLangone healthNational institutes of healthDepartment of biochemistryPancreatic cancer action networkLustgarten foundationLangone perlmutter cancer centerDivision of advanced research technologiesGrossman school of medicine

vimarsana © 2020. All Rights Reserved.